Skip to main content

Table 4 In-hospital management in secondary care hospitals

From: Improved treatment and prognosis after acute myocardial infarction in Estonia: cross-sectional study from a high risk country

 

Year 2001

Year 2007

Year 2011

P value for trend

n = 213

n = 360

n = 363

%

%

%

Medications

    

 Aspirin

88.3

86.4

85.7

0.383

 P2Y12-receptor inhibitors

0

10.6

26.4

<0.001

 Anticoagulants

85.4

92.8

95.0

<0.001

 Glycoprotein IIb/IIIa inh.

0.5

3.1

5.2

0.003

 Betablockers

76.1

77.8

73.0

0.384

 Nitrates

96.7

85.6

78.8

<0.001

 ACEi/ARB

37.1

62.2

55.9

<0.001

 Statins

5.6

30.8

49.0

<0.001

Cardiac catheterization

0

6.7

18.5

<0.001

Revascularization

0

4.2

14.3

<0.001

 PCI

0

4.2

14.3

<0.001

 CABG

0

0

0

-

Echocardiography

52.1

51.9

50.7

0.735

Referred to a tertiary care hospital

5.8

24.8

40.1

<0.001

Treatment for STEMI

n = 127

n = 185

n = 161

 

Reperfusion for STEMI

44.1

34.1

37.9

0.251

 Thrombolysis

44.1

34.1

29.2

0.008

 Primary PCI

0

0

8.7

-

Treatment for NSTEMI

n = 86

n = 175

n = 202

 

 PCI

0

4.6

10.4

0.002

 CABG

0

0

0

-

 Referred to a tertiary care hospital

5.8

10.3

28.2

<0.001

  1. Anticoagulants – low molecular weight heparins/unfractionated heparin, fondaparinux, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, P2Y12-receptor inhibitors – ticlopidine/clopidogrel/ticagrelol, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction